Y-mAbs Reports the Submission of Naxitamab's BLA to the US FDA for Relapsed/Refractory High-Risk Neuroblastoma
Shots:
- Y-mAbs has submitted the BLA the US FDA under the FDA’s Rolling Review process for naxitamab following the market closure on Mar 31- 2020
- The BLA submission is based on two P-II studies- 201 and 12-230 assessing the safety & efficacy of the therapy- which the company expects to present at a venue later this year
- Naxitamab is an investigational mAb- targeting GD2 having the potential to address the unmet medical needs of patients with relapsed/refractory high-risk neuroblastoma. The therapy was initially developed by MSK and exclusively licensed to Y-mAbs
Click here to read full press release/ article | Ref: Y-mAbs | Image: Y-mAbs
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com